NEW YORK (GenomeWeb News) – The European Commission plans to lead a project to support research seeking the validation of biomarkers for personalized cancer medicine through a funding call due out in December.
Funded through the European Research Era (ERA-NET), the multinational Translational Cancer Research (TRANSCAN) project aims to coordinate the research efforts and funding programs of European countries in translational cancer research.
The funding is for research projects based on novel ideas that propose "concrete progress" toward validating cancer biomarkers. Additionally, the projects should follow up on earlier laboratory or clinical investigations, according to an announcement from the EC Community Research and Development Information Service.
ERA-NET wants these projects to seek to validate biomarkers related to prevention, early detection, diagnosis, prediction of response or resistance to treatment, or prediction of risk of treatment toxicity. Proposals for this funding must involve at least three and as many as seven different groups from at least three countries, and they must include scientific and clinical research teams.
These consortia should be multi-disciplinary and include academic, clinical, epidemiological, or public health research teams and industry partners, and relevant data sets and resources within international groups should be shared.